Research progress on tofacitinib in the treatment of chronic actinic dermatitis
WU Hui
SHEN Haojia
HE Zezhi
CHEN Jiaoquan
LI Runxiang
ZHU Huilan
Abstract：Chronic actinic dermatitis(CAD)is a group of immune-mediated diseases charac-terized by photosensitivity.Tofacitinib,a Janus kinase(JAK)1/3 inhibitor,is currently the most extensively reported and widely used JAK inhibitor for the treatment of CAD.This article aims to briefly overview the background of CAD and tofacitinib,as well as to summarize the mechanisms of tofacitinib in the treatment of chronic actinic dermatitis,commonly used therapeutic dosages,spe-cific efficacy,and adverse effects.Additionally,a brief comparison of tofacitinib with other JAK inhibitors is also included.
Keywords：chronic actinic dermatitistofacitinibJAKsmall-molecule inhibitors
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 871-874 )